Mentor almost free of urology
This article was originally published in The Gray Sheet
Executive Summary
Firm announces definitive agreement to sell its Surgical Urology and Clinical and Consumer Healthcare divisions to Coloplast for $463 mil. on May 17. The transaction will enable Mentor to focus on the development of its aesthetics business (1"The Gray Sheet" April 3, 2006, p. 7). Mentor also reported that it has initiated a four-month Phase 1 study of its botulinum toxin type A product to treat pain associated with adult onset spasmodic torticollis/cervical dystonia...
You may also be interested in...
Mentor Finds Prospective Buyer For Urology Business In Coloplast
Mentor signaled March 27 that it has found a buyer for its urology business, furthering its shift to aesthetics medicine
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.